Tibsovo

News

FDA clears Servier's Tibsovo as first targeted drug for MDS

Servier has become the first company to get US approval for an IDH inhibitor as a treatment for myelodysplastic syndromes (MDS) after its Tibsovo drug was cleared by the F

News

FDA starts speedy review of Servier's Tibsovo in MDS

Servier could become the first company to bring an IDH inhibitor to market in the US for patients with myelodysplastic syndromes (MDS) next year, after the FDA started a p

News

FDA clears new first-line use for Servier's Tibsovo in AML

Servier is on course to get a return on its $1.8 billion takeover of Agios Pharma's oncology business after getting a key FDA approval for Tibsovo, the main asset in the deal.

News

ASH: Servier's Tibsovo poised for first-line used in AML

Servier has revealed the full data from its phase 3 trial of Tibsovo as a first-line treatment for acute myeloid leukaemia that it

FDA clears Servier's Tibsovo as first targeted drug for MDS

FDA starts speedy review of Servier's Tibsovo in MDS

FDA clears new first-line use for Servier's Tibsovo in AML

ASH: Servier's Tibsovo poised for first-line used in AML

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Tibsovo

Editor's Picks